Zacks.com on MSN2h
MYGN Stock Might Rise on Collaboration With CancerCARE
Myriad Genetics entered into an agreement with CancerCARE for Life to provide individuals within the latter's network with access to the MyRisk Hereditary Cancer Test.
Myriad Genetics, INTERLINK Partner To Enhance Access To Hereditary Cancer Testing
Myriad Genetics, Inc. (MYGN), a genetic and genomic tumor testing and precision medicine provider, and INTERLINK Care Management, ...
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and ...
Yahoo Finance3d
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management ...
Nasdaq6d
Myriad Genetics and Lumea Inc. Announce Integration of Advanced Molecular Diagnostic Tests into Digital Pathology Platform BxLink™
Myriad Genetics and Lumea Inc. have announced a partnership to integrate Myriad's Prolaris® Prostate Cancer Test and MyRisk® Hereditary Cancer Test into Lumea's digital pathology platform ...
Investing6d
Myriad Genetics secures patents for cancer MRD tests
SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of ...
Myriad Genetics, Inc.: Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced ...
Mena FN5d
Myriad Genetics And Cancercare For Life Announce Agreement To Advance Access To Myrisk With Riskscore Hereditary Cancer Test
(MENAFN- GlobeNewsWire - Nasdaq) SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine ...
KBC Group NV Purchases 3,334 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)
KBC Group NV raised its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 132.8% in the fourth quarter, ...
Morningstar5d
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States ...